Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Prepaid Assets (2020 - 2025)

Historic Prepaid Assets for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $21.7 million.

  • Tarsus Pharmaceuticals' Prepaid Assets rose 20926.59% to $21.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.7 million, marking a year-over-year increase of 20926.59%. This contributed to the annual value of $14.6 million for FY2024, which is 8619.73% up from last year.
  • As of Q3 2025, Tarsus Pharmaceuticals' Prepaid Assets stood at $21.7 million, which was up 20926.59% from $29.2 million recorded in Q2 2025.
  • In the past 5 years, Tarsus Pharmaceuticals' Prepaid Assets ranged from a high of $29.2 million in Q2 2025 and a low of $2.8 million during Q1 2021
  • Its 5-year average for Prepaid Assets is $7.6 million, with a median of $5.0 million in 2023.
  • Examining YoY changes over the last 5 years, Tarsus Pharmaceuticals' Prepaid Assets showed a top increase of 38849.63% in 2025 and a maximum decrease of 1181.83% in 2025.
  • Tarsus Pharmaceuticals' Prepaid Assets (Quarter) stood at $4.0 million in 2021, then increased by 17.85% to $4.8 million in 2022, then surged by 65.05% to $7.9 million in 2023, then soared by 86.2% to $14.6 million in 2024, then surged by 48.09% to $21.7 million in 2025.
  • Its Prepaid Assets stands at $21.7 million for Q3 2025, versus $29.2 million for Q2 2025 and $6.0 million for Q1 2025.